ONWARD Medical Reports First Quarter 2026 Results with Strong Commercial Momentum and Key Clinical Milestones

Why It Matters

The strong commercial uptake confirms demand for FDA‑cleared spinal‑cord stimulation, while the pivotal trial could open a new therapeutic market for autonomic dysfunction in SCI patients.

Key Takeaways

• 70 ARC‑EX systems supplied, first home‑use deliveries
• ARC‑EX now in 100+ US and European clinics
• Empower BP trial enrolled first patient; 12 sites active
• Q1 revenue €2 M ($2.2 M); cash €53.4 M ($58 M)
• €40 M ($44 M) equity raise extends runway to 2028

Pulse Analysis

ONWARD Medical’s Q1 performance underscores the growing appetite for neurotechnology solutions that translate laboratory breakthroughs into real‑world mobility gains. The ARC‑EX transcutaneous stimulation system, the first FDA‑cleared device of its kind, is now deployed in more than 100 rehabilitation centers, reflecting clinicians’ confidence in its ability to improve hand strength and sensation for chronic spinal‑cord injury patients. Home‑use shipments to veterans and other individuals further demonstrate a shift toward decentralized care, a trend that could accelerate adoption across the broader disability market.

Beyond commercial sales, ONWARD’s pipeline is gaining momentum with the Empower BP pivotal trial, the first global study to address blood‑pressure instability—a life‑threatening autonomic complication of spinal‑cord injury. The trial’s first enrollment and successful implant at Craig Hospital, coupled with 12 active sites across North America and Europe, position the ARC‑IM platform as a potential first‑in‑class therapy. Success in this study would not only expand the company’s addressable market but also set a precedent for combining spinal‑cord stimulation with brain‑computer interfaces to restore autonomic function.

Financially, the company posted €2 million (≈ $2.2 million) in revenue and bolstered its balance sheet with a €40 million (≈ $44 million) equity infusion, led by a €25 million (≈ $27 million) investment from EQT Life Sciences. This capital raise extends ONWARD’s runway to early 2028, providing runway for commercial scaling, regulatory milestones, and further R&D. Investors are likely to watch upcoming data from the Empower BP study and the rollout of ARC‑BCI implants, as both could catalyze revenue growth and solidify ONWARD’s position as a leader in restorative neurotechnology.